Avicena Announces the Commercial Launch of Its Nurigene(TM) Anti-Aging Skin Care Regimen
October 23 2007 - 8:30AM
PR Newswire (US)
PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a developer of novel
pharmaceutical and dermaceutical products, announced today the
commercial launch of its Nurigene skin care line, a scientifically
advanced skin care regimen. The Nurigene products leverage
Avicena's proprietary cellular energy technology to achieve
significant anti-aging benefits by enhancing the skin's ability to
regenerate and protect itself. Clinical studies have demonstrated
that the Nurigene skin care regimen offers multiple anti-aging
benefits including improvements in skin cell turnover, skin
firmness, skin elasticity and the skin's ability to retain
moisture. Results showed that skin treated with the Nurigene skin
care regimen had a statistically significant increase in cell
turnover of up to 43%, effectively encouraging younger skin cells
to reach the surface. In addition, results demonstrated that the
Nurigene skin care regimen produced a statistically significant
increase in skin firmness and elasticity. Findings also
demonstrated that Nurigene led to statistically significant
improvements in skin barrier function, effectively increasing in
the skin's ability to retain moisture. "The Nurigene skin care
regimen has demonstrated outstanding anti-aging benefits and has
garnered very positive feedback from consumers," said Belinda Tsao
Nivaggioli, Ph.D., Avicena's Chairman and Chief Executive Officer.
"By applying our proprietary technology platform to the development
of next-generation dermaceuticals, we are able to tap into the
growing $9 billion U.S. skin care market. By developing this skin
care regimen, we have created a product line that truly meets
women's skin health needs, while demonstrating our ability to
develop and commercialize products based on our cellular energy
platform." ABOUT NURIGENE(TM) The Nurigene product line is a
scientifically based line of skin care products formulated to
achieve significant anti-aging benefits by enhancing the
regeneration of healthier-looking skin and protecting against
damaging free radicals. The product line incorporates the Company's
proprietary Advanced Skin Nourishment(TM) technology, which is
designed to promote optimal cellular regeneration and protection by
providing critical nourishment to skin cells. For more information,
visit http://www.nurigene.com/. ABOUT AVICENA(TM) Avicena Group,
Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) is a Palo Alto, California
based late stage biotechnology company that develops central
nervous system therapeutics for neurodegenerative diseases. The
Company's core technologies, supported by a robust IP portfolio,
have broad applications in both pharmaceuticals and dermaceuticals.
Avicena's pharmaceutical program centers on rare neurological
disorders (orphan diseases). Near term, the Company plans to
initiate a confirmatory Phase III trial in ALS and a Phase III
trial in Huntington's disease to accompany the ongoing NIH Phase
III trial in Parkinson's disease. Avicena's science is well
established and its products are safe and well tolerated. Unlike
traditional biotechnology companies, Avicena's clinical programs
are largely funded by government and non-profit organizations.
Avicena presently derives revenue from the sale of proprietary
dermaceutical ingredients to skin care manufacturers. SAFE HARBOR
This release contains forward-looking statements that reflect,
among other things, management's current expectations, plans and
strategies, all of which are subject to known and unknown risks,
uncertainties and factors that may cause our actual results to
differ materially from those expressed or implied by these
forward-looking statements. Many of these risks are beyond our
ability to control or predict. See "Risk Factors" under "Item 6.
Management's Discussion and Analysis of Financial Condition and
Results of Operation" from our Annual Report on Form 10-KSB for the
year ended December 31, 2006, and other descriptions in the
Company's public filings with the Securities and Exchange
Commission for a discussion of such risks, including the Company's
need for additional funds, the Company's dependence on a limited
number of therapeutic compounds, the stage of the products the
Company is developing, uncertainties relating to clinical trials
and regulatory reviews, competition and dependence on collaborative
partners, the Company's ability to avoid infringement of the patent
rights of others, and the Company's ability to obtain adequate
patent protection and to enforce these rights. Because of these
risks, uncertainties and assumptions, you should not place undue
reliance on these forward-looking statements. Furthermore,
forward-looking statements speak only as of the date they are made.
Avicena does not undertake any obligation to update or review any
such forward-looking information, whether as a result of new
information, future events or otherwise. DATASOURCE: Avicena Group,
Inc. CONTACT: Investors, Sara Ephraim, +1-646-536-7002, , or Media,
Janine McCargo, +1-646-536-7033, , or Jason Rando, +1-646-536-7025,
, all of The Ruth Group, for Avicena Group, Inc. Web site:
http://www.nurigene.com/
Copyright